Results 231 to 240 of about 12,185,719 (426)

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

Precise and heritable gene targeting in rice using a sequential transformation strategy. [PDF]

Cell Rep Methods, 2023
Zhang W, Wang R, Kong D, Peng F, Chen M, Zeng W, Giaume F, He S, Zhang H, Wang Z, Kyozuka J, Zhu JK, Fornara F, Miki D.   +13 more
europepmc   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini, Ezgi Oner, Mark P. Ward, Sinead Hurley, Brian David Henderson, Faye Lewis, Stephen P. Finn, Gerard J. Fitzmaurice, John J. O'Leary, Sharon O'Toole, Lorraine O'Driscoll, Kathy Gately   +11 more
wiley   +1 more source

Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway. [PDF]

Immunol Rev, 2023
Dreismann AK, Hallam TM, Tam LC, Nguyen CV, Hughes JP, Ellis S, Harris CL.   +6 more
europepmc   +1 more source

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

Lethality rescue and long-term amelioration of a citrullinemia type I mouse model by neonatal gene-targeting combined to SaCRISPR-Cas9. [PDF]

Mol Ther Methods Clin Dev, 2023
Lisjak M, Iaconcig A, Guarnaccia C, Vicidomini A, Moretti L, Collaud F, Ronzitti G, Zentilin L, Muro AF.   +8 more
europepmc   +1 more source

Advancing Gene Selection in Oncology: A Fusion of Deep Learning and Sparsity for Precision Gene Selection [PDF]

arXiv
Gene selection plays a pivotal role in oncology research for improving outcome prediction accuracy and facilitating cost-effective genomic profiling for cancer patients. This paper introduces two gene selection strategies for deep learning-based survival prediction models.
arxiv  

Unraveling the metastasis‐preventing effect of miR‐200c in vitro and in vivo

Molecular Oncology, Volume 19, Issue 4, Page 1029-1053, April 2025.
Advanced tumors and ineffective cancer treatments can lead to metastases in distant organs. The sole expression of microRNA 200c (miR‐200c) in breast cancer cells is shown to significantly reduce metastasis formation in xenograft mouse models. Various in vitro analyses revealed impeded migratory behavior, upon miR‐200c expression, as one prerequisite ...
Bianca Köhler, Emily Brieger, Tom Brandstätter, Elisa Hörterer, Ulrich Wilk, Jana Pöhmerer, Anna Jötten, Philipp Paulitschke, Chase P. Broedersz, Stefan Zahler, Joachim O. Rädler, Ernst Wagner, Andreas Roidl   +12 more
wiley   +1 more source

Combinatorial gene targeting in primary human hematopoietic stem and progenitor cells. [PDF]

Sci Rep, 2022
Bäckström A, Yudovich D, Žemaitis K, Nilsén Falck L, Subramaniam A, Larsson J.   +5 more
europepmc   +1 more source